1. Role of integrase inhibitors in the treatment of HIV disease
2. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
3. Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals
4. D.A. Cooper, J.M. Gatell, J. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, J. Chen, R. Isaacs, H. Teppler, B.Y. Nguyen, Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus, 2007.
5. R. T. Steigbigel, P. Kumar, J. Eron, M. Schechter, M. Markowitz, M. Loufty, J. Zhao, R. Isaacs, B.Y. Nguyen, H. Teppler. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus, 2007.